Oncotarget Spreads Free Information

Oncotarget is a journal that publishes free papers online every week that are available to everyone. They also include an option for users to print these documents. The intent of Oncotarget is to spread the public’s knowledge by making various scientific research results available as soon as they are released. This will allow new discoveries to be shared more quickly and it will also build a bridge between different specialities in order to make the communities more accessible to each other. This also has worked to encourage collaboration in biomedical sciences. Oncotarget is considered to a revolutionary advance in the sharing network inside of the medical field. It is going to lead a great system of information and will greatly increase the access that everyone, including the public and medical professionals, have to the plethora of research that is being gathered every day. Download output styles at

Since their main goal is to end all disease, Oncotarget decided to focus specifically on combating cancer. They have made huge strides in the organization of all of this information and this has benefited the families of those who are suffering from cancer because they have access to a greater amount of information about the disease. The journal focuses specifically on potential therapy treatments and the current standing of treatment protocols. It focuses on the perspective of the patient and uses that to generate ideas for improved and more innovative management programs. They also worked with therapeutic agencies in order to further that sector. They supply their readers with all the evidence that is backing this research, and they discuss the potential therapies that could come into effect in the future. Oncotarget is thriving under the impressive leadership hands of Mikhail Blagosklonny and Andrei V. Gudkov, the editors in chief of the journal. Oncotarget runs through the intricate Index Medicus abstract. They run a highly efficient system and they are growing in popularity with authors in the medical field. In addition to their focus on oncology, Oncotarget also has in depth information on chromosomes, stems cells, neuroscience, cell diseases, gerotarget, and pathology. They also publish papers about age related disease, immunology, and endocrinology.

Read more:

Scott Rocklage: The Science and Biopharmaceutical Genius

Dr. Scott M. Rocklage is a renowned scientist, scholar, and entrepreneur based in Boston. He currently serves as a managing partner of 5 AM Venture Management, a California-based venture capital firm that financed science companies. Scott studied at the University of California, from where he graduated with a BSC in chemistry. He is also Ph.D. holder in Chemistry from the celebrated Massachusetts Institute of Technology. His research project was conducted at a lab named after Richard R. Schrock, a Nobel Prize in Chemistry Winner. Dr. Scott has more than 30 U.S. patents, either invented or co-invented, and over 100 peer-reviewed publications to his name.




Dr. Scott Rocklage boasts of over 30 years of experience in healthcare management. He served the executive director of Cubist Pharmaceuticals from 1994 to 2001 and the founding CEO from 1994 to 2003. He held research and development positions at Salutar and Catalytica Pharmaceuticals. Scott served as the president and CEO at Nycomed Salutar from 1990 to 1994. Between 1992 and 1994, he was the CEO, president, and board chairman at Nycomed Interventional. From 2007 to 2014, he was acting as the Director of Relypsa and Novira Therapeutics.


Dr. Scott’s strategic leadership skills were instrumental in the approval of three drugs, Omniscan, Cubicin, and Teslascan by The Food and Drugs Administration. He was the director of EPIRUS Biopharmaceuticals, Inc. from 2000 to 2004 and Achaogen Inc. from 2014 to 2016. Dr. Scott also served as the executive chairman of Miikana Therapeutics Inc. and Semprus. In 2016, Dr. Scott served briefly as the acting CEO at EPIRUS Biopharmaceuticals.


In 2012, Dr. Scott was appointed as the chairman of Novira Therapeutics, a position he holds to date. Since 2013, he has served as the board chairman at Cidara Therapeutics. Dr. Scott was a board director of Semprus BioSciences Corp. For over ten years now, Scott has served as a director of Pulmatrix, Inc. He joined 5 AM Venture Management in 2003 as a venture partner. A year later, Dr. Scott became a managing partner at the firm, a position he has held up to today. He also serves as a director at MDS Proteomics, a Spanish Biotechnology company.